No Data
Gilead Sciences in Charts: Revenue From Major Products Rises Y/Y in Q3
Gilead Rises as It Raises 2024 Sales, Non-GAAP EPS Outlook
Corteva Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results and Issued FY24 Sales Guidance With Its Midpoint Below Estimates.
Corteva Sees FY24 Operating EBITDA $3.35B-$3.45B; Operating EPS $2.50-$2.60; Free Cash Flow $1.5B-$2.0B.
Gilead Sciences Raises FY24 Product Sales Guidance From $27.10B - $27.50B To $27.80B - $28.10B
Gilead Sciences Non-GAAP EPS of $2.02 Beats by $0.47, Revenue of $7.55B Beats by $550M